Vetoquinol Reports Stable 2025 Financial Performance Amid Market Volatility

Vetoquinol posted annual sales of €526 million for 2025, marking a modest increase of 0.2% at constant exchange rates, despite a 2.5% decline on a reported basis due to currency impacts and product streamlining. Essential Products, a key part of their strategy, achieved sales of €334 million, up 4.1% at constant exchange rates.

The company's operating profit improved, with EBIT before amortization of acquired assets rising to €92 million, constituting 17.4% of total sales. Net result for the Group stood at €57 million, equating to 10.9% of sales. Vetoquinol's cash flow generation reached €72 million, bolstering its net cash position to €205.8 million by year-end.

CEO Matthieu Frechin emphasized the resilience of Vetoquinol’s business model and the strategic focus on expanding the Essentials range. The Board approved the financial statements, and a dividend of €0.93 per share is proposed for shareholder approval.